CSIMarket Company Name, Ticker, Customers, else..
 
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)
 
Price: $289.7400 $2.82 0.983%
Day's High: $289.7699890136719 Week Perf: 3.3 %
Day's Low: $ 281.88 30 Day Perf: -4.24 %
Volume (M): 190,286 52 Wk High: $ 326.63
Volume (M$): $ 0 52 Wk Avg: $221.75
Open: $286.92 52 Wk Low: $161.82



 Market Capitalization (Millions $) 6,327
 Shares Outstanding (Millions) 22
 Employees 47
 Revenues (TTM) (Millions $) 291
 Net Income (TTM) (Millions $) 197
 Cash Flow (TTM) (Millions $) 45
 Capital Exp. (TTM) (Millions $) 0

Business Description


Ligand Pharmaceuticals Inc. is a biopharmaceutical company that was founded in 1987 and is based in San Diego, California. The company's primary focus is on developing innovative medicines to treat serious diseases, and it has a diversified portfolio of drugs in various stages of development.

Ligand's primary area of expertise is in developing small molecule drugs that can selectively target specific cellular pathways to treat diseases. The company's technology platform is based on its proprietary Captisole technology, which is a drug delivery technology that improves the solubility and bioavailability of drugs. This technology has been licensed to various pharmaceutical companies for the development of their own drugs.

The company has a broad portfolio of drugs that are either in clinical trials or have been approved by regulatory agencies. Ligand's current portfolio includes drugs for the treatment of cancer, inflammatory diseases, metabolic disorders, and other diseases. Some of the drugs in the company's portfolio include Promactae (eltrombopag), Amgen's Omecamtiv Mecarbil (a cardiac muscle activator), and Evomelae (melphalan hydrochloride), among others.

Ligand has a business model that involves licensing its technology and intellectual property to pharmaceutical companies for the development of their own drugs. This allows the company to generate royalties and other revenue streams from these partnerships. It also allows the company to diversify its pipeline and reduce its reliance on any individual drug or therapeutic area.

The company has received numerous awards and recognitions for its innovative technology and drug development programs. In 2020, Ligand was named to Forbes America's Best Small Companies list, and its Captisole technology was named one of R&D Magazine's 100 most significant innovations of the year.

Overall, Ligand Pharmaceuticals Inc. is a leading biopharmaceutical company that is focused on developing innovative drugs to treat serious diseases. The company's technology platform and diversified pipeline make it a strong candidate for continued growth and success in the biotech industry.


   Company Address: 555 Heritage Drive, Suite 200 Jupiter 33458 FL
   Company Phone Number: 550-7500   Stock Exchange / Ticker: NASDAQ LGND


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        4.76% 
MRK        1.87% 
OGN        0.07% 
RYTM   -6.79%    
TEVA   -2.66%    
VRTX        1.9% 
• View Complete Report
   



Merger and Acquisition

Palvella Therapeutics Strengthens Leadership with Key CFO Appointment What It Means for Investors and Market Dynamics

Published Thu, Oct 17 2024 11:30 AM UTC

In a significant move aimed at bolstering its financial health and operational oversight, Palvella Therapeutics has appointed Matthew E. Korenberg as its new Chief Financial Officer (CFO). Korenberg joins Palvella with a wealth of experience, having held prominent positions at Ligand Pharmaceuticals and in healthcare investment banking at Goldman Sachs. This appointment sig...
Business Update

Ligand Pharmaceuticals Celebrates Major Milestone with FDA Approval of FILSPARI, Enhances Investment Appeal

Published Sat, Sep 7 2024 5:53 AM UTC

In the ever-evolving landscape of biotechnology and pharmaceuticals, the ability to innovate and provide solutions that address unmet medical needs is paramount. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has achieved a significant milestone in this regard, as its partner Travere Therapeutics, Inc. (NASDAQ: TVTX) has received full approval from the U.S. Food and Drug...
Business Update

The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement i...

Published Fri, Sep 6 2024 2:09 PM UTC

Sparsentan: A Breakthrough in IgA Nephropathy Treatment and its Impact on Ligand Pharmaceuticals The recent full FDA approval of FILSPARI (sparsentan) marks a significant advancement in the treatment of Immunoglobulin A Nephropathy (IgAN). Travere Therapeutics, in partnership with Ligand Pharmaceuticals, has developed sparsentan, the first non-immunosuppressive therapy tha...
Business Update

FDA Approves Ohtuvayre (Ensifentrine) First Inhaled Therapy with Novel Mechanism for COPD in Over 20 Years ...

Published Thu, Jun 27 2024 12:47 PM UTC

: The approval of Ohtuvayre (ensifentrine) by the U.S. Food and Drug Administration (FDA) marks pivotal progress in the treatment paradigm of chronic obstructive pulmonary disease (COPD). Developed by Verona Pharma plc in collaboration with Ligand Pharmaceuticals Incorporated, Ohtuvayre stands as the first inhaled drug with a novel mechanism of action for the maintenance tre...
Business Update

Expanding Horizons in Vaccination FDA Approves Mercks 21-Valent Pneumococcal Vaccine CAPVAXIVE

Published Tue, Jun 18 2024 12:47 PM UTC

In a significant leap forward for public health, Ligand Pharmaceuticals Incorporated recently announced that its pharmaceutical collaborator Merck has received approval from the U.S. Food and Drug Administration (FDA) for CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine. Known within the scientific community as V116 during its development phase, this vaccine has been gr...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 30.69
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 21.78
Price to Sales (Expected) -
Price to Book 6.54
PEG (TTM) -

Financial Strength Current
Quick Ratio 27.33
Working Capital Ratio 29.45
Leverage Ratio (MRQ) 1.26
Total Debt to Equity 1.16
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.44

Per Share Current
Earnings (TTM) 9.44 $
Revenues (TTM) 13.31 $
Cash Flow (TTM) 2.04 $
Cash 58.5 $
Book Value 44.31 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 6,181,745
Net Income per Employee (TTM) 4,196,170
Receivable Turnover Ratio (TTM) 4.89
Inventory Turnover Ratio (TTM) 2.91
Asset Turnover Ratio (TTM) 0.17

Profitability Ratios Current
Gross Margin (MRQ) 87.29 %
Operating Margin (MRQ) 13.49 %
Net Margin (MRQ) 76.16 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 17.12 %

Management Effectiveness Current
Return On Assets (TTM) 11.67 %
Return On Investment (TTM) 11.95 %
Return On Equity (TTM) 20.06 %
Dividend Yield -
Pay out Ratio (TTM) -



Ligand Pharmaceuticals Incorporated's Segments
Intangible Royalty Assets    110.36 % of total Revenue
Financial Royalty Assets    32.49 % of total Revenue
Royalty    142.86 % of total Revenue
Material Sales, Captisol    26.11 % of total Revenue
Contract revenue and income    12.24 % of total Revenue
Development and Licensing of Biopharmaceutical Assets    21.91 % of total Revenue
Filspari    39.08 % of total Revenue
Kyprolis    11.2 % of total Revenue
Qarziba    9.96 % of total Revenue
Capvaxive    6.73 % of total Revenue
Ohtuvayre inventors    4.39 % of total Revenue
Royalty Intangible, Other    12.61 % of total Revenue
Vaxneuvance    2.99 % of total Revenue
Contract and Revenue Income, Other    7.85 % of total Revenue
Contract revenue and other income    12.24 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.